


Monitoring Your Patients for Potentially Life-Threatening Digoxin Toxicity

DIGIFab[®]
digoxin immune fab (ovine)

As the Aging Population Grows, Digoxin Continues to Play a Role in the Management of Atrial Fibrillation and Heart Failure¹

Incidence of Atrial Fibrillation Has Steadily Climbed in Both Inpatient and Outpatient Settings²



The number of patients with atrial fibrillation is expected to reach **12.1 million in 2030**¹

Patients Aged ≥ 85 Years Are 2x as Likely to Have Toxic Digoxin Levels than Those 40-84 Years²

- Digoxin toxicity represents 3.3% of ED visits and 5.9% of hospitalizations due to adverse drug events in patients aged ≥ 85 years²
- Annual deaths due to digoxin are 4x higher than for lithium and warfarin combined¹

Results from a retrospective cohort study of 514,293 patients from 2001-2018 who received primary care and other healthcare services through a single integrated healthcare delivery network.²

INDICATIONS AND USAGE

DIGIFab is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose including:

Scroll down to see the common symptoms of digoxin toxicity and monitoring recommendations for patients taking digoxin

